Targeting endogenous proteins for degradation through the affinity-directed protein missile system

Luke J. Fulcher, Luke D. Hutchinson, Thomas J. Macartney, Craig Turnbull, Gopal P. Sapkota (Lead / Corresponding author)

Research output: Contribution to journalArticle

13 Citations (Scopus)
83 Downloads (Pure)

Abstract

Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in therapeutics. CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible for many genes. Similarly, RNA interference approaches necessitate prolonged treatments, can lead to incomplete knockdowns, and are often associated with off-target effects. Targeted proteolysis can overcome these limitations. In this report, we describe an Affinity-directed PROtein Missile (AdPROM) system that harbours the von Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to polypeptide binders that selectively bind and recruit endogenous target proteins to the CUL2-E3 ligase complex for ubiquitination and proteasomal degradation. By using synthetic monobodies that selectively bind the protein tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selectively binds the human ASC protein, we demonstrate highly efficient AdPROM-mediated degradation of endogenous SHP2 and ASC in human cell lines. We show that AdPROM-mediated loss of SHP2 in cells impacts SHP2 biology. This study demonstrates for the first time that small polypeptide binders that selectively recognise endogenous target proteins can be exploited for AdPROM-mediated destruction of the target proteins.
Original languageEnglish
Article number170066
Pages (from-to)1-11
Number of pages11
JournalOpen Biology
Volume7
DOIs
Publication statusPublished - 10 May 2017

Fingerprint

Missiles
Proteolysis
Degradation
Proteins
Ubiquitin-Protein Ligases
Binders
Clustered Regularly Interspaced Short Palindromic Repeats
Single-Domain Antibodies
Genes
Gene Knockout Techniques
Peptides
Protein Tyrosine Phosphatases
Ubiquitination
Ports and harbors
RNA Interference
Cells
RNA
Cell Line
Substrates
Research

Keywords

  • proteolysis
  • AdPROM
  • ubiquitination
  • SHP2
  • ASC
  • nanobody

Cite this

Fulcher, Luke J. ; Hutchinson, Luke D. ; Macartney, Thomas J. ; Turnbull, Craig ; Sapkota, Gopal P. / Targeting endogenous proteins for degradation through the affinity-directed protein missile system. In: Open Biology. 2017 ; Vol. 7. pp. 1-11.
@article{cea57f04c10b4f72b47d7cc3d354660c,
title = "Targeting endogenous proteins for degradation through the affinity-directed protein missile system",
abstract = "Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in therapeutics. CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible for many genes. Similarly, RNA interference approaches necessitate prolonged treatments, can lead to incomplete knockdowns, and are often associated with off-target effects. Targeted proteolysis can overcome these limitations. In this report, we describe an Affinity-directed PROtein Missile (AdPROM) system that harbours the von Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to polypeptide binders that selectively bind and recruit endogenous target proteins to the CUL2-E3 ligase complex for ubiquitination and proteasomal degradation. By using synthetic monobodies that selectively bind the protein tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selectively binds the human ASC protein, we demonstrate highly efficient AdPROM-mediated degradation of endogenous SHP2 and ASC in human cell lines. We show that AdPROM-mediated loss of SHP2 in cells impacts SHP2 biology. This study demonstrates for the first time that small polypeptide binders that selectively recognise endogenous target proteins can be exploited for AdPROM-mediated destruction of the target proteins.",
keywords = "proteolysis, AdPROM, ubiquitination, SHP2, ASC, nanobody",
author = "Fulcher, {Luke J.} and Hutchinson, {Luke D.} and Macartney, {Thomas J.} and Craig Turnbull and Sapkota, {Gopal P.}",
note = "This study was funded by the UK Medical Research Council (MRC) (grant number MC_UU_12016/3). LJF and LDH are supported by the UK MRC Prize PhD studentships. LJF also receives funding from Queens College Scholarship, University of Dundee. GPS is supported by the UK MRC and the pharmaceutical companies supporting the Division of Signal Transduction Therapy (DSTT) at the University of Dundee (Boehringer-Ingelheim, GlaxoSmithKline, Merck-Serono).",
year = "2017",
month = "5",
day = "10",
doi = "10.1098/rsob.170066",
language = "English",
volume = "7",
pages = "1--11",
journal = "Open Biology",
issn = "2046-2441",
publisher = "The Royal Society",

}

Targeting endogenous proteins for degradation through the affinity-directed protein missile system. / Fulcher, Luke J.; Hutchinson, Luke D.; Macartney, Thomas J.; Turnbull, Craig ; Sapkota, Gopal P. (Lead / Corresponding author).

In: Open Biology, Vol. 7, 170066, 10.05.2017, p. 1-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting endogenous proteins for degradation through the affinity-directed protein missile system

AU - Fulcher, Luke J.

AU - Hutchinson, Luke D.

AU - Macartney, Thomas J.

AU - Turnbull, Craig

AU - Sapkota, Gopal P.

N1 - This study was funded by the UK Medical Research Council (MRC) (grant number MC_UU_12016/3). LJF and LDH are supported by the UK MRC Prize PhD studentships. LJF also receives funding from Queens College Scholarship, University of Dundee. GPS is supported by the UK MRC and the pharmaceutical companies supporting the Division of Signal Transduction Therapy (DSTT) at the University of Dundee (Boehringer-Ingelheim, GlaxoSmithKline, Merck-Serono).

PY - 2017/5/10

Y1 - 2017/5/10

N2 - Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in therapeutics. CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible for many genes. Similarly, RNA interference approaches necessitate prolonged treatments, can lead to incomplete knockdowns, and are often associated with off-target effects. Targeted proteolysis can overcome these limitations. In this report, we describe an Affinity-directed PROtein Missile (AdPROM) system that harbours the von Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to polypeptide binders that selectively bind and recruit endogenous target proteins to the CUL2-E3 ligase complex for ubiquitination and proteasomal degradation. By using synthetic monobodies that selectively bind the protein tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selectively binds the human ASC protein, we demonstrate highly efficient AdPROM-mediated degradation of endogenous SHP2 and ASC in human cell lines. We show that AdPROM-mediated loss of SHP2 in cells impacts SHP2 biology. This study demonstrates for the first time that small polypeptide binders that selectively recognise endogenous target proteins can be exploited for AdPROM-mediated destruction of the target proteins.

AB - Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in therapeutics. CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible for many genes. Similarly, RNA interference approaches necessitate prolonged treatments, can lead to incomplete knockdowns, and are often associated with off-target effects. Targeted proteolysis can overcome these limitations. In this report, we describe an Affinity-directed PROtein Missile (AdPROM) system that harbours the von Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2 (CUL2) E3 ligase complex, tethered to polypeptide binders that selectively bind and recruit endogenous target proteins to the CUL2-E3 ligase complex for ubiquitination and proteasomal degradation. By using synthetic monobodies that selectively bind the protein tyrosine phosphatase SHP2 and a camelid-derived VHH nanobody that selectively binds the human ASC protein, we demonstrate highly efficient AdPROM-mediated degradation of endogenous SHP2 and ASC in human cell lines. We show that AdPROM-mediated loss of SHP2 in cells impacts SHP2 biology. This study demonstrates for the first time that small polypeptide binders that selectively recognise endogenous target proteins can be exploited for AdPROM-mediated destruction of the target proteins.

KW - proteolysis

KW - AdPROM

KW - ubiquitination

KW - SHP2

KW - ASC

KW - nanobody

U2 - 10.1098/rsob.170066

DO - 10.1098/rsob.170066

M3 - Article

VL - 7

SP - 1

EP - 11

JO - Open Biology

JF - Open Biology

SN - 2046-2441

M1 - 170066

ER -